A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma

BACKGROUND: The objective of this randomized placebo-controlled study was to investigate the efficacy and safety of clarithromycin in combination with bortezomib–cyclophosphamide–dexamethasone (VCD) in patients with newly diagnosed multiple myeloma eligible for high-dose therapy. METHODS: Patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Gregersen, Henrik, Do, Trung, Kristensen, Ida Bruun, Frølund, Ulf Christian, Andersen, Niels Frost, Nielsen, Lene Kongsgaard, Andersen, Christen Lykkegaard, Klausen, Tobias Wirenfeldt, Vangsted, Annette Juul, Abildgaard, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090810/
https://www.ncbi.nlm.nih.gov/pubmed/30123673
http://dx.doi.org/10.1186/s40164-018-0110-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090810/
https://www.ncbi.nlm.nih.gov/pubmed/30123673
http://dx.doi.org/10.1186/s40164-018-0110-0

Ejemplares similares